As the US pharmaceuticals unit of Swiss drug giant Novartis AG, Novartis Pharmaceuticals Corporation (NPC) helps with the development, manufacturing, marketing, and sales of its parent company's products in the US. Its product lines address a range of ailments including cardiovascular and respiratory diseases, central nervous system disorders, cancers, bone and skin conditions, infectious diseases, and organ transplant complications. NPC's key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin. NPC markets its products through an in-house sales team.
NPC represents the best of both worlds for parent Novartis AG: It is part of the global Novartis Pharmaceuticals division, which accounts for more than 55% of the parent company's annual revenues, and it is also a major player in the US market, which is Novartis' largest geographic segment accounting for about a third of sales.
Most of NPC's preclinical research efforts are conducted through US-based affiliate Novartis Institutes for BioMedical Research (NIBR), while clinical-stage development programs are conducted at Novartis sites around the globe.
The company widens its offerings in the US market through a number of methods including internal research programs, licensing agreements, and acquisitions. In 2015, the company received approval from the US FDA for its Cosentyx product for the treatment of moderate-to-severe plaque psoriasis in adults eligible for systemic therapy (drug absorbed through the bloodstream) or phototherapy (light therapy). In 2014, the FDA approved its Signifor long-acting release (LAR) product for injectable suspension, for intramuscular use, for treating patients with acromegaly where surgery is ineffective or not an option. That year Novartis also received FDA approval for its Xolair product for the treatment of a chronic hives illness -- chronic idiopathic urticaria (CIU).